EUCTR2005-003444-53-IT进行中（未招募）不适用
A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg administered every 28 days for 6 months in acromegalic patients with uncontrolled disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A randomized, multicentre, open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitisSatunnaistettu, avoin, vertaileva monikeskustutkimus siklosporiinista ja infliximabista kortikosteroidille reagoimattoman vaikean haavaisen paksusuolitulehduksen hoidossa. - CYSIF STUDYEUCTR2006-005299-42-FIGroupe d'Etude Thérapeutique des Affections Inflammatoires Digestives (G.E.T.A.I.D.)100
进行中（未招募）
1 期
Cabazitaxel versus Docetaxel both with Prednisone in Patients with Metastatic Castration Resistant Prostate CancerEUCTR2010-022064-12-SEsanofi-aventis R&D1,170
进行中（未招募）
1 期
Cabazitaxel versus Docetaxel both with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancermetastatic Castration Resistant Prostate cancerMedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022064-12-DEsanofi-aventis R&D1,170
进行中（未招募）
1 期
Cabazitaxel versus Docetaxel both with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancermetastatic Castration Resistant Prostate cancerMedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022064-12-PLsanofi-aventis R&D1,170
进行中（未招募）
不适用
Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy - FIRSTANAmetastatic Castration Resistant Prostate cancerMedDRA version: 14.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022064-12-ITsanofi-aventis R&D1,170